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Mild cognitive impairment (MCI) is defi ned as a 
transitional or preclinical state between the cognitive 
decline of normal aging and the cognitive decline due 
to Alzheimer’s dementia. It involves problems with 
memory, language, thinking and judgment that are 
greater than is expected for one’s age. General cogni-
tive functions remain preserved and changes are not 
severe enough to interfere with daily life and usual 
activities. A person with MCI may be aware of mem-
ory function problems as well as his family and close 
friends who may also notice a change.
 Th e annual prevalence of MCI in the USA is 
estimated to 3-4% in the eighth decade of life in the 
general population, and 19.2% for ages 65-74 years, 
27.6% for ages 75-84 years, and 38% for ages 85 years 
and older [1-3]. In the Mayo Clinic Study of Aging a 
prevalence of MCI in men was found [4].
Th ere are two diff erent subtypes of MCI: amnestic 
and nonamnestic MCI. In the amnestic form of MCI 
memory impairment predominates. Th is subtype of 
MCI is more often a precursor to clinical Alzheimer’s 
disease. In the nonamnestic subtype of MCI the most 
common cognitive impairment is probably the damage 
of the executive functions. Th is form of nonamnestic 
MCI may be associated with cerebrovascular disease 
or with frontotemporal dementia [5]. A considerable 
percentage of persons with MCI progresses to demen-
tia, about 10–15% per year [6].
Th ere have been discussions about whether MCI 
must be viewed as a separate nosological entity at in-
creased risk of dementia or a prodrome of Alzheimer’s 
disease. Th e concept of MCI was defi ned by Petersen 
and all. in 1997, and was restricted to only memory 
impairment leading to the identifi cation of people 
at a high risk of progression to Alzheimer’s disease 
[7]. Some patients with MCI regain normal cogni-
tive function, some remain stable and some show a 
progression to diff erent types of dementia. Due to this 
heterogeneity of the clinical presentation, as well as 
the outcome of numerous MCI subjects, Petersen ex-
tended his previous concept to a syndrome-type clas-
sifi cation : amnestic MCI which is characterised by 
the following criteria: -complaining about memory, 
preferably corroborated by an informant or by the sub-
jects themselves;– objectively impaired memory func-
tion in relation to the age and education;– preserved 
general cognitive function;– intact basic activities of 
daily life; and– no dementia [8].
Several medical conditions and lifestyle factors 
may be linked to an increased risk of cognitive change 
although the evidence for these risk factors is less 
clear-cut. Th ese risk factors include: diabetes, smok-
ing, depression, high blood pressure, elevated choles-
terol, lack of physical exercise, infrequent participa-
tion in mentally or socially stimulating activities. 
For the objective measurement of cognitive deteri-
oration standard neuropsychological tests are applied, 
in which poor performance on delayed recall and ex-
ecutive functions indicate a high risk of progression 
towards AD [9,10]. Th ose tests are complimentary to 
the mini-mental state examination. Supplementary 
information from a knowledgeable informant (e.g. a 
family member) concerning the individual’s memory 
abilities can be particularly helpful as some patients 
may be unaware of their cognitive changes [11]. Many 
patients with MCI suff er from anxiety and depres-
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sion, thereby it is sometimes diffi  cult to make the cor-
rect diagnosis. Other disorders, such as frontotempo-
ral dementia, Lewy body dementia or vascular origin 
of cognitive impairment might be suggested. 
Biomarkers in the cerebrospinal fl uid are help-
ful to diff erentiate between MCI and normal ageing 
and to identify patients at risk for progression to AD. 
Th e markers that have been studied include total tau, 
phosphorylated tau and beta-amyloid 1–42 [12,13]. 
Follow-up studies performed by Hansson et all. dem-
onstrated that concentrations of these markers in 
MCI patients were strongly associated with further 
development of AD [14]. Th e consistent feature of nu-
merous studies points out that increased total tau and 
phosphotau concentrations are highly sensitive.
Investigations with magnetic resonance imag-
ing (MRI) have demonstrated medial temporal lobe 
atrophy in people with MCI compound who were 
cognitively normal individuals, and this atrophy is 
predictive of progression to dementia [15-18]. Longi-
tudinal hippocampal volume losses in these patients 
are closely associated with increasing hyperphos-pho-
rylated tau [19].
On Positron emission tomography (PET) changes 
of regional cerebral metabolic rate for glucose (CM-
RGlc) were found in many subjects with MCI. Th ese 
changes were predictive of clinical progression to Al-
zheimer disease within a follow-up period of more 
than a year [20-23]. Th e reduction of CMRGlc in AD 
typical brain regions were related to elevated phosphor-
tau levels and combined to assessment of the APOE 
genotype improved identifi cation of high-risk patients 
[24,25]. Acetylcholine esterase activity as a marker of 
cholinergic activity is reduced in AD [26]. Th e cholin-
ergic system is important for memory functions, and 
therefore the decrease in AChE activity might be a 
predictor of conversion from MCI to AD. 
Another promising tracers for detection of deposi-
tion of amyloid are 11C-labelled arylbenzothiazoles, 
known as „Pittsburgh Compound-B“ [27]. In cortical 
areas PIB retention was increased in AD and corre-
lated inversely with cerebral glucose metabolism [28]. 
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